Question 1

What is China — National Medical Products Administration?

Accepted Answer

China — National Medical Products Administration is a Entity.

Question 2

How often does China — National Medical Products Administration appear in global news?

Accepted Answer

Tracked across 8 news events drawn from 53 articles.

Question 3

When was China — National Medical Products Administration first tracked by Ergen?

Accepted Answer

First tracked on Apr 08, 2026.

Question 4

When was China — National Medical Products Administration last mentioned in news?

Accepted Answer

Last active on Jul 03, 2026.

Question 5

What is China — National Medical Products Administration's current news sentiment?

Accepted Answer

Aggregate sentiment score: 0 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is China — National Medical Products Administration in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 8 events.

Question 7

What is the most recent event involving China — National Medical Products Administration?

Accepted Answer

China NMPA Accepts LEROCHOL BLA (Jun 26, 2026, 8 articles).

Question 8

Who is China — National Medical Products Administration most connected to?

Accepted Answer

Top relationships: American Society of Clinical Oncology, American Society of Clinical Oncology, China.

Question 9

How did the "China NMPA Accepts LEROCHOL BLA" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for Lerociclib, which is a crucial regulatory step for the drug's potential approval and availability in China.

Question 10

How did the "ORPATHYS Approved for Gastric Cancer in China" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration granted conditional approval for ORPATHYS (savolitinib) for the treatment of gastric cancer, enabling its commercialization in China.

Question 11

How did the "HUTCHMED Fanregratinib Phase II Results" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration accepted the New Drug Application for fanregratinib and granted it priority review, indicating a potential expedited path to market approval in China.

Question 12

How did the "Junshi Biosciences licenses roconkibart to Fosun Wanbang" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration accepted the new drug application for roconkibart in December 2025, indicating progress in the regulatory approval process for the drug.

Question 13

How did the "Brii Bio HBV Trial Results" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration's Center for Drug Evaluation granted BRII-179 and elebsiran Breakthrough Therapy Designation, and Brii Biosciences has reached preliminary alignment with them regarding a potential registrational study for ENRICH.

Question 14

How did the "AGAMREE Phase 1 Study Results" event impact China — National Medical Products Administration?

Accepted Answer

The China — National Medical Products Administration is mentioned as having approved AGAMREE for Duchenne muscular dystrophy in China, indicating the drug's established regulatory status.

Question 15

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.